Biocon inks trial research pact with Spaulding; Canada approves hep C drug Incivek; artifical "skin" is bulletproof;

@FierceBiotech: A group of researchers hope to grow spare heart parts from embryonic stem cells within 5 years. Report | Follow @FierceBiotech

@JohnCFierce: Fresh off the Zelboraf win, Roche CEO Schwan does the visionary thing on pharma's bright future. Story | Follow @JohnCFierce

@RyanMFierce: A computerized blueprint for starving cancer cells: Group created the first genome-scale model of cancer cell. Item | Follow @RyanMFierce

@MaureenFierce: New way to treat C. difficile? Drug stimulates cells in the gut that can neutralize toxins. Report | Follow @MaureenFierce

> India's Biocon has forged a pact with Spaulding Clinical Research to offer clinical trial services to biotech companies. Item

> Malaysia's biotech development agency is seeking new funds to back drug developers doing late-stage work. Story

> Canadian officials have approved Vertex's new hep C drug Incivek. Report

Pharma News

@FiercePharma: On top of 280 Irish jobs saved in Pfizer plant buyout. RT @lisamjarvis: Amgen to add Dublin plant, creating 100 jobs: Report | Follow @FiercePharma

> Boehringer unit to exit contract manufacturing. Report

> Seattle Genetics prices Adcetris above $100K. Article

> U.S. officials, docs step into drug-shortage fray. Item

Biotech IT News

> Perfect algorithm proves elusive for DREAM teams. More

> A computerizing blueprint for starving cancer. Article

> Computational method rapidly discovers new uses for approved drugs. Details

> Vital models emerging to enable personalized cancer care. Report

> Deloitte grabs drug regulatory tech in new buyout. News

Medical Device News

> TheraSolve closes first financing round. Report

> Sources: Kinetic recieves higher buyout offer. Details

> Report: Medrad to buy Pathway for $125M. News

> Intersect ENT CEO discusses Propel implant. More

> Tangent taps Accuri, HandyLab vet as CEO. Story

And Finally... A researcher in Utah has been developing bulletproof "skin" made from silk and milk from transgenic goats. Story

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.